CLL
MCID: LKM071
MIFTS: 77

Leukemia, Chronic Lymphocytic (CLL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Chronic Lymphocytic

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic:

Name: Leukemia, Chronic Lymphocytic 57 75 38 40
Chronic Lymphocytic Leukemia 38 12 76 53 37 29 6 43 15 73
Cll 57 12 53 75
B-Cell Chronic Lymphocytic Leukemia 12 59 75
B-Cell Chronic Lymphoid Leukemia 12 59
Chronic Lymphatic Leukemia 12 75
Lymphoplasmacytic Leukemia 12 73
Small Lymphocytic Lymphoma 59 73
Leukemia, Lymphocytic, Chronic, B-Cell 44
Lymphocytic Leukemia Chronic B-Cell 55
Leukemia, Lymphocytic, Chronic 53
Leukemia Lymphocytic Chronic 55
Leukemia, Chronic Lymphatic 57
Lymphoma Small Lymphocytic 55
Chronic Lymphoid Leukemia 75
B-Cll 59

Characteristics:

Orphanet epidemiological data:

59
b-cell chronic lymphocytic leukemia
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
associated with susceptibility loci on chromosome 11p11 (clls1, ), 13q14 (clls2, ), 9q34.1 (clls3, ), 6p25.3 (clls4, ), and 11q24.1 (clls5, )


HPO:

32
leukemia, chronic lymphocytic:
Inheritance somatic mutation autosomal dominant somatic cell mutation


Classifications:



External Ids:

OMIM 57 151400
Disease Ontology 12 DOID:1040
ICD10 33 C91.1 C91.10
ICD9CM 35 204.1
MeSH 44 D015451
NCIt 50 C3163
SNOMED-CT 68 51092000 92814006
Orphanet 59 ORPHA67038
UMLS via Orphanet 74 C0855095 C1868683 C0023434
ICD10 via Orphanet 34 C91.1
MESH via Orphanet 45 D015451
MedGen 42 C0023434
KEGG 37 H00005
SNOMED-CT via HPO 69 124975008 277473004

Summaries for Leukemia, Chronic Lymphocytic

MedlinePlus : 43 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic lymphocytic leukemia (CLL), there are too many lymphocytes, a type of white blood cell. CLL is the second most common type of leukemia in adults. It often occurs during or after middle age, and is rare in children. Usually CLL does not cause any symptoms. If you have symptoms, they may include Painless swelling of the lymph nodes in the neck, underarm, stomach, or groin Fatigue Pain or a feeling of fullness below the ribs Fever and infection Weight loss Tests that examine the blood, bone marrow, and lymph nodes diagnose CLL. Your doctor may choose to just monitor you until symptoms appear or change. Treatments include radiation therapy, chemotherapy, surgery to remove the spleen, and targeted therapy. Targeted therapy uses substances that attack cancer cells or block the growth and spread of cancer cells. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Chronic Lymphocytic, also known as chronic lymphocytic leukemia, is related to leukemia, chronic lymphocytic 2 and cll/sll, and has symptoms including fatigue, angina pectoris and edema. An important gene associated with Leukemia, Chronic Lymphocytic is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Phospholipase-C Pathway. The drugs Arzerra and Campath have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are cellular immunodeficiency and chronic lymphatic leukemia

NIH Rare Diseases : 53 Chronic lymphocytic leukemia (CLL) is a cancer of the lymphocytes (a type of white blood cell). It begins in the stem cells of the bone marrow and then spreads to the blood. Over time, CLL may also spread to the lymph nodes and other organs, including the liver, spleen and lungs. Early signs and symptoms of CLL may include swollen lymph nodes, fatigue, weight loss, loss of appetite, fever, night sweats and/or frequent infections. The underlying cause of CLL is unknown. It usually occurs in people with no family history of the condition, but familial cases have been reported. Treatment options depend on many factors, including the stage of the condition, blood cell counts, and whether the CLL has recurred (come back). Treatment may not be necessary until a person develops symptoms or there is other evidence of rapid cancer progression. The chance of recovery and life expectancy vary from person to person. While most people with CLL live at least 5 to 10 years, some do not survive more than 2 to 3 years after the diagnosis.

OMIM : 57 Chronic lymphocytic leukemia (CLL) is a common neoplasia of B lymphocytes in which these cells progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival (summary by Quesada et al., 2012). (151400)

UniProtKB/Swiss-Prot : 75 Leukemia, chronic lymphocytic: A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

Wikipedia : 76 Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many... more...

Related Diseases for Leukemia, Chronic Lymphocytic

Diseases in the Lymphocytic Leukemia family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic
Leukemia, Chronic Lymphocytic 1 Leukemia, Chronic Lymphocytic 3
Leukemia, Chronic Lymphocytic 4 Leukemia, Chronic Lymphocytic 5
Acute Lymphocytic Leukemia Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 508)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 2 34.6 TP53 PTPN11 NRAS KRAS HRAS BRAF
2 cll/sll 34.2 ZAP70 TP53 CCND1 ATM
3 lymphocytic leukemia 31.8 ATM PTPN11 TP53 ZAP70
4 melanoma 31.1 TP53 NRAS MIR19A MIR141 BRAF
5 adenocarcinoma 30.9 TP53 KRAS HRAS CCND1 BRAF
6 myelodysplastic syndrome 30.8 TP53 PTPN11 NRAS KRAS HRAS
7 myeloid leukemia 30.7 TP53 PTPN11 NRAS HRAS
8 adenoma 30.6 TP53 KRAS CCND1 BRAF
9 gastric adenocarcinoma 30.6 TP53 NRAS KRAS HRAS CCND1 BRAF
10 glioma 30.5 TP53 POT1 MIR19A CCND1 BRAF
11 prolymphocytic leukemia 30.5 ATM CCND1 ZAP70
12 myeloma, multiple 30.4 TP53 PTPN11 NRAS MIR19A KRAS IKZF3
13 lymphoma, non-hodgkin, familial 30.3 TP53 NRAS CCND1 BRAF ATM
14 lung cancer 30.3 TP53 NRAS MIR19A MIR141 KRAS HRAS
15 thyroid cancer 30.3 TP53 NRAS KRAS HRAS CCND1 BRAF
16 pancreas adenocarcinoma 30.3 TP53 KRAS HRAS CCND1
17 leukemia, acute myeloid 30.3 TP53 PTPN11 NRAS KRAS HRAS
18 glioblastoma 30.3 TP53 NRAS HRAS CCND1 BRAF
19 hepatocellular carcinoma 30.3 TP53 NRAS MIR19A MIR141 KRAS HRAS
20 endometrial cancer 30.1 TP53 KRAS HRAS CCND1 BRAF
21 leukemia, chronic lymphocytic 4 12.4
22 leukemia, chronic lymphocytic 5 12.4
23 leukemia, chronic lymphocytic 1 12.4
24 leukemia, chronic lymphocytic 3 12.4
25 richter's syndrome 11.7
26 leukemia 11.6
27 immunotactoid glomerulopathy 11.5
28 chronic leukemia 11.4
29 t-cell large granular lymphocyte leukemia 11.2
30 immunotactoid or fibrillary glomerulopathy 11.2
31 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.1
32 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.1
33 leukemia, b-cell, chronic 10.7
34 large intestine cancer 10.5 TP53 PTPN11 NRAS KRAS HRAS CCND1
35 bladder urothelial carcinoma 10.5 TP53 NRAS KRAS HRAS CCND1 BRAF
36 differentiated thyroid carcinoma 10.5 TP53 NRAS KRAS HRAS BRAF
37 renal cell carcinoma, papillary, 1 10.5 TP53 NRAS HRAS BRAF ATM
38 lung cancer susceptibility 3 10.5 TP53 NRAS KRAS HRAS CCND1 BRAF
39 liver angiosarcoma 10.5 TP53 NRAS KRAS HRAS
40 melanoma, cutaneous malignant 1 10.5 TP53 POT1 NRAS HRAS BRAF
41 intestinal benign neoplasm 10.5 TP53 KRAS HRAS CCND1
42 pulmonic stenosis 10.5 PTPN11 KRAS HRAS BRAF
43 cardiofaciocutaneous syndrome 1 10.5 PTPN11 KRAS HRAS BRAF
44 squamous cell carcinoma, head and neck 10.5 TP53 MIR19A MIR141 HRAS CCND1 BRAF
45 lung squamous cell carcinoma 10.5 TP53 PTPN11 KRAS HRAS BRAF
46 ovarian serous cystadenocarcinoma 10.5 TP53 NRAS HRAS BRAF
47 colorectal adenocarcinoma 10.5 TP53 KRAS HRAS BRAF
48 colonic disease 10.5 TP53 KRAS HRAS CCND1
49 hematologic cancer 10.5 ZAP70 TP53 PTPN11 HRAS ATM
50 adenoid cystic carcinoma 10.5 TP53 KRAS HRAS CCND1 ATM

Comorbidity relations with Leukemia, Chronic Lymphocytic via Phenotypic Disease Network (PDN): (show all 13)


Acquired Thrombocytopenia Acute Cystitis
Agammaglobulinemia, X-Linked Anemia, Autoimmune Hemolytic
Bronchitis Chronic Leukemia
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Leukemia Lymphoid Leukemia
Neutropenia

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic:



Diseases related to Leukemia, Chronic Lymphocytic

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic

Symptoms via clinical synopsis from OMIM:

57
Hematology:
chronic lymphatic leukemia

Laboratory Abnormalities:
recurring t(11,14) and t(14,19)(q32,q13.1) translocations

Immunology:
impaired cellular and humoral immunity


Clinical features from OMIM:

151400

Human phenotypes related to Leukemia, Chronic Lymphocytic:

32
# Description HPO Frequency HPO Source Accession
1 cellular immunodeficiency 32 HP:0005374
2 chronic lymphatic leukemia 32 HP:0005550

UMLS symptoms related to Leukemia, Chronic Lymphocytic:


fatigue, angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.05 HRAS KRAS
2 Decreased viability GR00106-A-0 10.05 KRAS
3 Decreased viability GR00107-A-1 10.05 ZAP70
4 Decreased viability GR00221-A-1 10.05 HRAS KRAS NRAS POT1 ZAP70
5 Decreased viability GR00221-A-2 10.05 HRAS KRAS ZAP70
6 Decreased viability GR00221-A-3 10.05 HRAS NRAS POT1
7 Decreased viability GR00221-A-4 10.05 POT1
8 Decreased viability GR00301-A 10.05 KRAS
9 Decreased viability GR00342-S-1 10.05 ZAP70
10 Decreased viability GR00342-S-2 10.05 ZAP70
11 Decreased viability GR00381-A-1 10.05 KRAS
12 Decreased viability GR00402-S-2 10.05 HRAS KRAS NRAS POT1 ZAP70
13 Decreased cell migration GR00055-A-1 9.55 ATM BRAF HRAS KRAS ZAP70
14 Reduced mammosphere formation GR00396-S 9.23 ATM BRAF CCND1 HRAS KRAS NRAS

MGI Mouse Phenotypes related to Leukemia, Chronic Lymphocytic:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.97 ATM BRAF CCND1 HRAS KRAS NRAS
2 craniofacial MP:0005382 9.95 BRAF CCND1 HRAS KRAS NRAS PTPN11
3 digestive/alimentary MP:0005381 9.91 BRAF CCND1 HRAS KRAS NRAS PTPN11
4 integument MP:0010771 9.91 ATM BRAF CCND1 HRAS KRAS NRAS
5 neoplasm MP:0002006 9.81 ATM BRAF CCND1 HRAS IKZF3 KRAS
6 pigmentation MP:0001186 9.35 BRAF KRAS NRAS PTPN11 TP53
7 respiratory system MP:0005388 9.17 BRAF CCND1 HRAS KRAS PTPN11 TP53

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic

FDA approved drugs:

(show all 8)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Arzerra 18 49 OFATUMUMAB GlaxoSmithKline October 2009
2
Campath 18 49 ALEMTUZUMAB Berlex Laboratories May 2001
3
Clolar 18 49 CLOFARABINE Genzyme December, 2004
4
Gazyva 18 49 OBINUTUZUMAB Genentech October of 2013
5
Imbruvica 18 49 IBRUTINIB Pharmacyclics November of 2013/February 2014
6
Revlimid 18 49 LENALIDOMIDE Celgene June 2013
7
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
8
Zydelig 18 49 IDELALISIB Gilead July 2014

Drugs for Leukemia, Chronic Lymphocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 585)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
3
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
4
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 439693 40926
5
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
7
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
8
Ofatumumab Approved Phase 4,Phase 3,Phase 2,Phase 1 679818-59-8 6918251
9
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
11
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
14
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
15
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
16
Valganciclovir Approved, Investigational Phase 4,Phase 2,Not Applicable 175865-60-8 64147
17
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
19
Prednisolone hemisuccinate Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
20 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Bendamustine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
32 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
34 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
35 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
36 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
45 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
48 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1748)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Low Grade Lymphoma Unknown status NCT01698866 Phase 4
3 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
4 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
5 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
6 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
7 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
8 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
9 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4 Ofatumumab
10 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
11 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
12 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
13 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
14 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
15 Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
16 Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
17 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
18 A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
19 The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Unknown status NCT01518959 Phase 3 Cholecalciferol;oleum neutralicum
20 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
21 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
22 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
23 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
24 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
25 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
26 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
27 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
28 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
29 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
30 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
31 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
32 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
33 Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia Active, not recruiting NCT02612311 Phase 3 TGR-1202;Chlorambucil
34 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Recruiting NCT03406156 Phase 3 Obinutuzumab;Bendamustine;Venetoclax
35 Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
36 Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Active, not recruiting NCT02301156 Phase 3 Ublituximab;ibrutinib
37 Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
38 A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Recruiting NCT03734016 Phase 3 BGB-3111;Ibrutinib
39 Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
40 Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia Terminated NCT00416910 Phase 3 Fludarabine;Cyclophosphamide;Mitoxantrone
41 Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01659021 Phase 3 Idelalisib;Ofatumumab
42 Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
43 Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia Recruiting NCT03737981 Phase 3 Ibrutinib;Venetoclax
44 FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
45 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
46 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Active, not recruiting NCT02005471 Phase 3 Bendamustine;Venetoclax;Rituximab
47 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed NCT01500083 Phase 3 Bendamustine at a dose of 100 mg/m2;Bendamustine at a dose of 120 mg/m2
48 Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
49 Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia Active, not recruiting NCT02477696 Phase 3 ACP-196;ibrutinib
50 A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). Active, not recruiting NCT02980731 Phase 3 Venetoclax

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Lymphocytic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Chronic Lymphocytic:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Leukemia, Chronic Lymphocytic:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: leukemia, lymphocytic, chronic, b-cell

Genetic Tests for Leukemia, Chronic Lymphocytic

Genetic tests related to Leukemia, Chronic Lymphocytic:

# Genetic test Affiliating Genes
1 Chronic Lymphocytic Leukemia 29

Anatomical Context for Leukemia, Chronic Lymphocytic

MalaCards organs/tissues related to Leukemia, Chronic Lymphocytic:

41
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Myeloid, Spleen
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Chronic Lymphocytic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Chronic Lymphocytic

Articles related to Leukemia, Chronic Lymphocytic:

(show top 50) (show all 4342)
# Title Authors Year
1
Ex-Vivo Signal Transduction Studies in Chronic Lymphocytic Leukemia. ( 30350193 )
2019
2
Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia Cells. ( 30350194 )
2019
3
Culture and Harvest of CpG-Stimulated Peripheral Blood or Bone Marrow in Chronic Lymphocytic Leukemia. ( 30350195 )
2019
4
Analysis of Common Abnormalities Seen in Chronic Lymphocytic Leukemia Using Fluorescence In Situ Hybridization. ( 30350196 )
2019
5
Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia. ( 30350197 )
2019
6
Methods for Investigating VLA-4 (CD49d/CD29) Expression and Activation in Chronic Lymphocytic Leukemia and Its Clinical Applications. ( 30350200 )
2019
7
Extracellular Flux Assays to Determine Oxidative Phosphorylation and Glycolysis in Chronic Lymphocytic Leukemia Cells. ( 30350202 )
2019
8
Measurement of Leukemic B-Cell Growth Kinetics in Patients with Chronic Lymphocytic Leukemia. ( 30350203 )
2019
9
Minimal Residual Disease Quantification in Chronic Lymphocytic Leukemia: Clinical Significance and Flow Cytometric Methods. ( 30350209 )
2019
10
Measurement of miRNAs in Chronic Lymphocytic Leukemia Patient Samples by Quantitative Reverse Transcription PCR. ( 30350212 )
2019
11
Genome Sequencing and Analysis Methods in Chronic Lymphocytic Leukemia. ( 30350214 )
2019
12
High-Throughput Sequencing of the T-Cell Receptor Beta Chain Gene Repertoire in Chronic Lymphocytic Leukemia. ( 30350216 )
2019
13
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma. ( 29934061 )
2018
14
Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib. ( 29760835 )
2018
15
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. ( 29449433 )
2018
16
A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus. ( 29950535 )
2018
17
Simultaneous finding of chronic lymphocytic leukemia and residual hairy cell leukemia using a lymphocyte-binding anti-CD antibody microarray. ( 29636954 )
2018
18
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? ( 29402474 )
2018
19
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
20
Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. ( 29976738 )
2018
21
Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. ( 29911929 )
2018
22
Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia. ( 29277764 )
2018
23
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. ( 29450641 )
2018
24
Necrobiotic xanthogranuloma associated with chronic lymphocytic leukemia. ( 29485184 )
2018
25
Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. ( 28565930 )
2018
26
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab. ( 29526963 )
2018
27
Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. ( 29976737 )
2018
28
Gamma heavy chain disease evolving during the progression of chronic lymphocytic leukemia. ( 29315075 )
2018
29
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. ( 29762141 )
2018
30
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the Phase 3b GREEN study. ( 29976743 )
2018
31
Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). ( 29437555 )
2018
32
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
33
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells. ( 29432497 )
2018
34
A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways. ( 29080742 )
2018
35
Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. ( 28679298 )
2018
36
Refractory Abdominal Pain in a Patient with Chronic Lymphocytic Leukemia: Be Wary of Acquired Angioedema due to C1 Esterase Inhibitor Deficiency. ( 29545957 )
2018
37
Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16A years of epidemiological data from the province of Girona, Spain. ( 29383469 )
2018
38
Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro. ( 29353760 )
2018
39
Disseminated cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia. ( 29428267 )
2018
40
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
41
Paraneoplastic pemphigus with anti-desmocollin 3 autoantibodies and chronic lymphocytic leukemia. ( 29599682 )
2018
42
Rare Coexistence of Acute Monoblastic Leukemia with Chronic Lymphocytic Leukemia. ( 30524762 )
2018
43
Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently. ( 29052253 )
2018
44
An Unusual Case Report: Occurrence of Renal Cell Carcinoma, Basal Cell Carcinoma and Chronic Lymphocytic Leukemia in a Case of Papillary Thyroid Carcinoma Treated with Radioactive Iodine. ( 30510343 )
2018
45
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. ( 30458196 )
2018
46
Insect Bite-Like Reaction with Bullous Lesions Mimicking Bullous Pemphigoid in a Patient with Chronic Lymphocytic Leukemia. ( 30065590 )
2018
47
Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature. ( 30442199 )
2018
48
Pericardial Involvement with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case of Constrictive Pericarditis. ( 30140781 )
2018
49
Blood and Guts: Diarrhea from Colonic Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 30155841 )
2018
50
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature. ( 29524963 )
2018

Variations for Leukemia, Chronic Lymphocytic

ClinVar genetic disease variations for Leukemia, Chronic Lymphocytic:

6 (show top 50) (show all 210)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
3 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
4 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
5 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
7 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
9 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
10 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
11 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
12 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
13 BRAF NM_004333.4(BRAF): c.1391G> A (p.Gly464Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913348 GRCh37 Chromosome 7, 140481417: 140481417
14 BRAF NM_004333.4(BRAF): c.1391G> A (p.Gly464Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913348 GRCh38 Chromosome 7, 140781617: 140781617
15 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
16 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 GRCh38 Chromosome 7, 140753334: 140753334
17 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 GRCh38 Chromosome 7, 140753354: 140753354
18 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
19 MYD88 NM_002468.4(MYD88): c.794T> C (p.Leu265Pro) single nucleotide variant Uncertain significance rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
20 MYD88 NM_002468.4(MYD88): c.794T> C (p.Leu265Pro) single nucleotide variant Uncertain significance rs387907272 GRCh38 Chromosome 3, 38141150: 38141150
21 PTPN11 NM_002834.4(PTPN11): c.215C> T (p.Ala72Val) single nucleotide variant Conflicting interpretations of pathogenicity rs121918454 GRCh37 Chromosome 12, 112888199: 112888199
22 PTPN11 NM_002834.4(PTPN11): c.215C> T (p.Ala72Val) single nucleotide variant Conflicting interpretations of pathogenicity rs121918454 GRCh38 Chromosome 12, 112450395: 112450395
23 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
24 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Likely pathogenic rs397516896 GRCh38 Chromosome 7, 140753355: 140753355
25 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
26 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh38 Chromosome 7, 140753333: 140753333
27 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
28 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh38 Chromosome 12, 25227341: 25227341
29 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh37 Chromosome 4, 153247289: 153247289
30 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh38 Chromosome 4, 152326137: 152326137
31 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 NCBI36 Chromosome 4, 153466739: 153466739
32 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
33 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh38 Chromosome 1, 114713909: 114713909
34 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 NCBI36 Chromosome 1, 115058053: 115058053
35 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
36 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
37 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh38 Chromosome 17, 7673823: 7673823
38 TP53 NM_001126115.1(TP53): c.401G> A (p.Gly134Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs193920774 GRCh37 Chromosome 17, 7577141: 7577141
39 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918453 GRCh38 Chromosome 12, 112450394: 112450394
40 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918453 GRCh37 Chromosome 12, 112888198: 112888198
41 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
42 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh37 Chromosome 11, 534285: 534285
43 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
44 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
45 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh38 Chromosome 17, 7674250: 7674250
46 TP53 NM_000546.5(TP53): c.713G> A (p.Cys238Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
47 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
48 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs786201838 GRCh38 Chromosome 17, 7674953: 7674953
49 TP53 NM_000546.5(TP53): c.578A> G (p.His193Arg) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
50 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286

Expression for Leukemia, Chronic Lymphocytic

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic.

Pathways for Leukemia, Chronic Lymphocytic

Pathways related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show top 50) (show all 111)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.44 BRAF CCND1 HRAS IGHG1 KRAS NRAS
2
Show member pathways
13.14 BRAF HRAS KRAS NRAS TP53 ZAP70
3
Show member pathways
13.13 ATM CCND1 HRAS KRAS NRAS TP53
4
Show member pathways
13.08 ATM CCND1 HRAS KRAS NRAS TP53
5
Show member pathways
13 BRAF HRAS KRAS NRAS TP53 ZAP70
6
Show member pathways
13 ATM HRAS KRAS NRAS TP53 ZAP70
7
Show member pathways
12.95 BRAF CCND1 HRAS KRAS NRAS
8
Show member pathways
12.94 BRAF CCND1 HRAS KRAS NRAS
9 12.92 BRAF CCND1 HRAS KRAS NRAS TP53
10
Show member pathways
12.92 BRAF CCND1 HRAS KRAS NRAS PTPN11
11
Show member pathways
12.88 ATM HRAS KRAS NRAS TP53
12
Show member pathways
12.85 BRAF CCND1 HRAS KRAS PTPN11
13 12.84 BRAF HRAS KRAS NRAS TP53
14
Show member pathways
12.84 BRAF CCND1 HRAS KRAS NRAS TP53
15
Show member pathways
12.81 BRAF HRAS KRAS NRAS PTPN11 ZAP70
16
Show member pathways
12.81 ATM BRAF CCND1 HRAS KRAS NRAS
17
Show member pathways
12.8 HRAS KRAS NRAS PTPN11 TP53
18
Show member pathways
12.8 BRAF CCND1 HRAS KRAS NRAS
19
Show member pathways
12.79 BRAF HRAS KRAS NRAS PTPN11 TP53
20
Show member pathways
12.76 BRAF HRAS KRAS NRAS TP53
21
Show member pathways
12.67 HRAS KRAS NRAS PTPN11 TP53
22
Show member pathways
12.66 BRAF HRAS KRAS NRAS PTPN11
23
Show member pathways
12.61 BRAF CCND1 HRAS KRAS NRAS TP53
24
Show member pathways
12.58 BRAF HRAS KRAS NRAS TP53
25
Show member pathways
12.53 ATM HRAS KRAS NRAS TP53
26
Show member pathways
12.53 CCND1 HRAS KRAS NRAS PTPN11 ZAP70
27
Show member pathways
12.51 HRAS KRAS NRAS PTPN11 ZAP70
28
Show member pathways
12.51 BRAF CCND1 HRAS KRAS NRAS
29
Show member pathways
12.5 HRAS KRAS NRAS PTPN11
30
Show member pathways
12.49 CCND1 HRAS KRAS NRAS
31
Show member pathways
12.49 CCND1 HRAS KRAS NRAS PTPN11
32
Show member pathways
12.48 BRAF HRAS KRAS NRAS
33
Show member pathways
12.47 HRAS KRAS NRAS PTPN11
34
Show member pathways
12.47 BRAF HRAS KRAS PTPN11
35
Show member pathways
12.47 CCND1 HRAS IGHG1 PTPN11 TP53
36
Show member pathways
12.46 BRAF HRAS KRAS NRAS PTPN11
37
Show member pathways
12.45 ATM CCND1 MIR19A TP53
38 12.45 ATM CCND1 HRAS KRAS NRAS TP53
39
Show member pathways
12.45 BRAF HRAS IGHG1 KRAS NRAS PTPN11
40
Show member pathways
12.42 HRAS KRAS NRAS PTPN11
41
Show member pathways
12.41 BRAF HRAS KRAS NRAS
42
Show member pathways
12.4 HRAS KRAS NRAS PTPN11 ZAP70
43
Show member pathways
12.4 BRAF CCND1 HRAS KRAS NRAS PTPN11
44
Show member pathways
12.37 BRAF HRAS KRAS NRAS
45 12.37 CCND1 HRAS KRAS NRAS TP53
46
Show member pathways
12.35 ATM KRAS POT1 PTPN11 TP53
47
Show member pathways
12.35 BRAF HRAS KRAS NRAS PTPN11
48
Show member pathways
12.31 HRAS KRAS NRAS PTPN11
49 12.3 HRAS KRAS NRAS PTPN11
50
Show member pathways
12.3 HRAS KRAS NRAS PTPN11

GO Terms for Leukemia, Chronic Lymphocytic

Biological processes related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.77 ATM BRAF HRAS KRAS TP53
2 MAPK cascade GO:0000165 9.76 BRAF HRAS KRAS NRAS
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.58 HRAS KRAS NRAS
4 cytokine-mediated signaling pathway GO:0019221 9.55 CCND1 IGHG1 KRAS PTPN11 TP53
5 replicative senescence GO:0090399 9.49 ATM TP53
6 negative regulation of telomerase activity GO:0051974 9.48 POT1 TP53
7 mitotic G1 DNA damage checkpoint GO:0031571 9.43 CCND1 TP53
8 response to isolation stress GO:0035900 9.32 HRAS KRAS
9 regulation of telomere maintenance via telomerase GO:0032210 9.26 ATM POT1
10 cellular response to gamma radiation GO:0071480 9.13 ATM HRAS TP53
11 Ras protein signal transduction GO:0007265 8.92 HRAS KRAS NRAS TP53

Molecular functions related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.02 ATM BRAF HRAS KRAS NRAS

Sources for Leukemia, Chronic Lymphocytic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....